Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Add-On Payments For New Dialysis Drugs Limited To ‘Innovative’ Products

Executive Summary

Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.

You may also be interested in...



Medicare Dialysis Bundle And New Drugs: Will Transitional Payments Work For Korsuva, Vadadustat?

Quick provider uptake will be key for upcoming new drugs covered by the Medicare end stage renal disease prospective payment system.

Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%

Amgen looks forward to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.

US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best

Recent developments in US federal government regulation of prescription drug pricing and reimbursement.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel